About Matthew

Matthew Hemington has substantial experience in representing emerging growth companies, venture capitalists, corporate investors and public companies. He has advised emerging technology companies in matters ranging from startup incorporation and counseling to day-to-day representation of public companies. He has assisted his clients with obtaining financing, technology and licensing matters, public offerings, M&A, strategic relationships and executive compensation matters. 

I have been practicing in the Silicon Valley for more than 25 years, and I still get excited about helping clients build great companies.

View full bio

Experience

  • Intersect ENT Acquires Fiagon

    • Intersect ENT Acquires Fiagon

    Cooley advised Intersect ENT, a commercial drug delivery company, on its agreement to acquire Fiagon, a developer of clinical navigation systems. Partner Matt Hemington led the Cooley team.

    Related contacts

    Matthew Hemington
    Partner, Palo Alto

    Related Practices & Industries

    Mergers and Acquisitions
    Medtech

  • Si-Bone: $92.5 Million Follow-On

    • Si-Bone: $92.5 Million Follow-On

    Cooley advised Si-Bone, a developer of surgical instruments, in its $92.5 million follow-on offering.

    Related contacts

    Matthew Hemington
    Partner, Palo Alto

    Related Practices & Industries

    Capital Markets
    Medtech

  • Intersect ENT Closes Convertible Offering

    • Intersect ENT Closes Convertible Offering

    Cooley advised Intersect ENT on its $65 million convertible notes financing. Intersect ENT is a commercial drug delivery company committed to improving the quality of life for patients with ear, nose and throat conditions.

    Related contacts

    Matthew Hemington
    Partner, Palo Alto

    Related Practices & Industries

    Debt Finance
    Medtech

  • 1Life Healthcare: $257.3 Million Follow-On

    • 1Life Healthcare: $257.3 Million Follow-On

    Cooley advised 1Life Healthcare, a membership-based primary care platform with seamless digital health and inviting in-office care, in its $257.3 million follow-on offering.

    Related contacts

    Matthew Hemington
    Partner, Palo Alto

    Related Practices & Industries

    Capital Markets
    Digital Health
    Healthcare

  • Si-Bone Initial Public Offering

    • Si-Bone Initial Public Offering

    October 10, 2018

    Cooley advised Si-Bone on its $124.2 million initial public offering of 8,280,000 shares of common stock. Matthew Hemington and John McKenna led the Cooley team advising Si-Bone.

    Morgan Stanley and Merrill Lynch acted as the lead book-running managers for the offering. Canaccord Genuity and JMP Securities acted as co-managers for the offering.

    Si-Bone is a medical device company that has pioneered a treatment for sacroiliac joint dysfunction that often causes severe lower back pain. The company’s shares now trade on the Nasdaq Global Market under the symbol “SIBN.”

    Related contacts

    Matthew Hemington
    Partner, Palo Alto
    John McKenna
    Partner, Palo Alto
    Kate Nichols
    Partner, Palo Alto

    Related Practices & Industries

    Capital Markets
    Life Sciences and Healthcare
View more

Admissions and credentials

  • California

Rankings and accolades

Best Lawyers in America: Venture Capital Law, Securities/Capital Markets Law and Corporate Law


Memberships and affiliations

  • American Bar Association (ABA)

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.